


---

<b>Product Name</b>	: ZLDI-8
<b>Cat. No.</b>	: PC-35373
<b>CAS No.</b>	: 667880-38-8
<b>Molecular Formula</b>	: C <sub>24</sub> H <sub>23</sub> N <sub>3</sub> O <sub>3</sub> S
<b>Molecular Weight</b>	: 433.526
<b>Target</b>	: Matrix Metalloproteinase (MMP)
<b>Solubility</b>	: 10 mM in DMSO



## Biological Activity

ZLDI-8 (IAC-8) is a novel Notch signaling pathway inhibitor for Notch activating/cleaving enzyme **ADAM-17**, significantly decreases the level of NICD and accumulation of NICD in the nucleus.

ZLDI-8 (IAC-8) exhibits cytotoxic activity against MHCC97-H cells with IC<sub>50</sub> of 5.32 uM, reduces the expression of pro-survival/anti-apoptosis regulators, Survivin and cIAP1/2, also increases the expression of epithelial marker E-Cadherin and reduces mesenchymal markers N-Cadherin and Vimentin in HCC cells.

ZLDI-8 (IAC-8) significantly disrupted the activity of Notch pathway in HCC cells and inhibits the epithelial-mesenchymal transition (EMT) process of HCC cells.

ZLDI-8 (IAC-8) treatment enhances the susceptibility of HCC cells to Sorafenib, Etoposide, and Paclitaxel both in vitro and in vivo.

## References

Zhang Y, et al. *Cell Death Dis.* 2018 Jul 3;9(7):743.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com

---